Option chain shows key data for Affymax's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Affymax.

Affymax (OTC:AFFY) Stock, Option Chain

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AACS

AAON

AAUKF

ACDSF

ACGL

ACIA

ACLS

ADBE

ADSK

ADYYF

AFFY

AFGC

AIQUY

AJMPF

AKAM

ALCO

ALFVY

ALLE

ALLT

AMADY

AMAT

AMBC

AMED

AMIGF

AMRC

AMWD

ANCUF

ANSLY

ANSS

AOMFF

AOMOY

APAM

APPF

ARBV

ARES

ASAZF

ASAZY

ASHTY

ASPN

ASYS

ATCMF

ATLC

ATRC

ATVI

ATZAF

AUDC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BAESY

BANF

BASI

BATRA

BCPC

BCUCY

BEVFF

BF-A

BF-B

BHOOY

BIOS

BKRKY

BLDP

BLSP

BMDPY

BORT

BPOP

BRK-A

BRK-B

Stocks That Hit 52-Week Highs On Friday

ACMR

ACRE

ADYEY

AJRD

ALMFF

AOIFF

AOSL

ARDC

ARMK

ARVN

ASMLF

ATLKY

AXELF

BBDC

BLDR

BMBYF

BMCH

BRKR

BTBIF

BTDPY

BURBY

CACI

CCLAY

CCOI

CCXI

CDAY

CFFA

CGNX

CHRYY

CIADF

COHU

COLL

CPIVF

CPRT

CRVL

CSGP

CSLLY

Stocks That Hit 52-Week Highs On Thursday

ABBV

ALNY

GILD

Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints

Affymax Inc

Affymetrix Announces Distribution Agreement with Luminex

Dividends

Management

Affymax Announces $0.05/Share Special Distribution; Names Jonathan Couchman as Pres, CEO

13D Filing from Jonathan Couchman on Affymax Shows 5% Stake, Includes Language on Talks, Cites $0.10/Share Offer

Affymax Board Has Decided to Dissolve Co.

Affymax, Takeda Announce Termination of Omontys, Will Withdraw US NDA

Contracts

Affymax Announcers Termination of Omontys License Agreement

KaloBios Pharmaceuticals (Nasdaq: <a class="ticker" href="/stock/kbio#Nasdaq">KBIO</a>) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The company expects this transition will be completed in the October-November time frame. Mr. Cross was previously Chief Financial Officer of Affymax (Nasdaq: <a class="ticker" href="/stock/affy#Nasdaq">AFFY</a>), a publicly traded biopharmaceutical company. KaloBios previously announced Mr. Cooper's decision to retire in order to dedicate more time to family and personal interests.

"Herb is a well respected finance professional with over sixteen years of experience, including seven years in senior roles in the biotech industry," said David Pritchard, President and Chief Executive Officer of KaloBios. "His prior work in monoclonal antibody companies and his broad leadership roles in public companies will be invaluable to KaloBios as we focus on our next stage of growth and development. We look forward to Herb joining our executive team and transitioning into his new role over the next several weeks."

"I would also like to express my appreciation to Jeff Cooper for his outstanding work and dedication to KaloBios as he moves toward his retirement later this year," Mr. Pritchard concluded.

"KaloBios has an interesting and diverse pipeline of monoclonal antibody therapeutic candidates in clinical development, in important areas of unmet medical need. I look forward to working with the KaloBios team to help build shareholder value and realize the potential of KaloBios' business," said Mr. Cross.

Mr. Cross served as Chief Financial Officer at Affymax for over two years, where he was a member of the executive team and was responsible for all financial functions, including accounting, financial planning and analysis, treasury and risk management, corporate governance, stock administration and tax functions. Before becoming CFO, he served as the company's Vice President, Finance. Mr. Cross previously served as Vice President, Finance for Facet Biotech Corporation, a publicly held, development-stage biotechnology company. Before joining Facet, he was corporate controller at PDL BioPharma, a publicly held bio-pharmaceutical company specializing in monoclonal antibody technology, with more than $400 million in annual revenues. Before that, he held positions of increasing responsibility, including Vice President, Finance, at Neoforma, Inc., a public e-commerce software company. Mr. Cross began his career at Arthur Andersen, LLP, and earned a B.S. from the Haas School of Business at the University of California, Berkeley.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. 

Currently, KaloBios has three drug development programs: 

KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a planned 150 patient Phase 2 study in the United States, Europe and Australia. 
KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi and is being developed for the prevention and treatment of Pa infection. KaloBios has retained rights for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios received Orphan Drug designation from the European Commission for KB001-A for the treatment of Pa lung infection in CF. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation. 
KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies. 
All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

For more information on KaloBios Pharmaceuticals, please visit our web site at <a href="http://www.kalobios.com.">http://www.kalobios.com.</a>

Forward Looking Statements
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's clinical development of KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013 and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

KBIO

Herb C. Cross to Join KaloBios as Chief Financial Officer

Affymax Shares Rise; May be Attributed to Seeking Alpha Post Saying Shares Could Have Tremendous Upside If Omontys Returns to Market

Managed properly, retirement plans enhance wealth due to the power of compound interest. Ideally, the beneficiary saves enough money to live comfortably during retirement without having to worry about outliving his savings. Yet, the very stock market he relies on to grow his wealth also poses the risk of losing some or all of his hard-earned retirement wealth. 

How can you protect your retirement plans?

Diversify

Imagine some unfortunately soul who invested his entire $500,000 savings into Affymax (OTC: <a class="ticker" href="/stock/affy#OTC">AFFY</a>) on February 22. On February 25, he would have lost over $425,000 due to the firm's recall of its core product. Today, he'd have less than $32,000 – just over six percent of the assets he held four months ago. 

While extreme, the above can happen to any stock if its issuer experiences a severe problem. As such, it is important to diversify one's assets to reduce exposure to a catastrophic loss. 

Diversification can be accomplished by spreading retirement savings across multiple asset categories. Doing so limits the risk of a catastrophic loss because, under a given economic condition, certain categories tend to benefit while others suffer. 

Invest More Conservatively as Retirement Nears

As a general rule of thumb, younger investors should pump their retirement savings into aggressive investments. For example, a college grad opening his first 401(k) would want to select mostly stocks. 

However, as he ages, the same investor should gradually move his assets into more conservative selections. For instance, his portfolio may be allocated according to the following percentages at various ages:

<ul><li>Age 25: stocks (100%)</li>
<li>Age 35: stocks (80%), bonds (15%), cash (5%)</li>
<li>Age 45: stocks (60%), bonds (30%), cash (10%)</li>
<li>Age 55: stocks (35%), bonds (35%), cash (30 %)</li>
<li>Age 65: stocks (20%), bonds (50 %), cash (30%)</li>
</ul>

As demonstrated, he'd gradually move away from stocks in favor of bonds and cash as he ages to develop a more conservative portfolio and reduce risk. While doing so would lessen his exposure to market upswings and thus reduce his potential returns, he'd be less likely to lose enough money to jeopardize his retirement plans. 

The Bottom Line

By diversifying your assets and investing more conservatively as you age, you'll protect your assets from severe losses while participating in the financial gains of the market. However, doing so, while simple in concept, is often challenge for a novice investor. With this in mind, seek advice from a financial professional if you are not confident in your abilities to select the appropriate investments to manage market risk.

Psychology

Topics

Personal Finance

How to Protect Your Retirement Plans

As previously announced, on May&nbsp;28, 2013, Affymax,&nbsp;Inc. (OTC: <a class="ticker" href="/stock/affy#OTC">AFFY</a>) 
 received a determination letter (the “Determination Letter”) from the 
 Nasdaq Stock Market LLC (“Nasdaq”) delisting the Company's common stock 
 from Nasdaq as of June 6, 2013. Effective on that date, its common stock 
 was immediately eligible for and now trades for quotation on the OTCQB, 
 an electronic quotation service operated by OTC Markets Group Inc. for 
 eligible securities traded over-the-counter. The Company expects that 
 its common stock will also trade on the OTC Bulletin Board. The 
 Company's common stock will continue to trade under the symbol AFFY.
 Senior Leadership Changes
 Effective June 6, 2013, Herb Cross was terminated as Chief Financial 
 <a href="http://www.benzinga.com/pressreleases/13/06/b3656346/affymax-announces-update-on-listing-senior-leadership-and-board-changes">See full press release</a>

Guidance

Global

Affymax Appoints Rich Brenner CEO

NeuroMetrix (NASDAQ: <a class="ticker" href="/stock/nuro#NASDAQ">NURO</a>) dropped 16.16% to $2.18 after the company announced $5 million placement of preferred stock with single institutional investor. 

 Epizyme (NASDAQ: <a class="ticker" href="/stock/epzm#NASDAQ">EPZM</a>) dipped 4.04% to $25.70 after the company announced closing of its IPO and full exercise of over-allotment option. 

 JA Solar Holdings Co (NASDAQ: <a class="ticker" href="/stock/jaso#NASDAQ">JASO</a>) fell 11.45% to $6.73 on the company's unsustainable margin strength. 

 Zogenix (NASDAQ: <a class="ticker" href="/stock/zgnx#NASDAQ">ZGNX</a>) dropped 10.27% to $1.32 on company's announcement to cut 55 employees.

 Ampio Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/ampe#NASDAQ">AMPE</a>) declined 11.18% to $5.97 after a day of high volume trading. 

 Affymax (NASDAQ: <a class="ticker" href="/stock/affy#NASDAQ">AFFY</a>) tumbled 19.78% to $1.25 after a recent delisting letter from NASDAQ.

 Tesaro (NASDAQ: <a class="ticker" href="/stock/tsro#NASDAQ">TSRO</a>) dipped 10.36% to $39.80 after Monday's tremendous gain. 

 Giant Interactive Group (NYSE: <a class="ticker" href="/stock/ga#NYSE">GA</a>) dropped 10.65% to $7.59 after the company announced secondary offering of 15,137,853 American Depositary Shares by selling shareholders.

Economics

AMPE

EPZM

JASO

NURO

TSRO

ZGNX

Afternoon Market Losers

Synta Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/snta#NASDAQ">SNTA</a>) is down 32.32% to $4.99 after Synta reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of Ganetespib in second-line non-small cell lung cancer.

Infinity Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/infi#NASDAQ">INFI</a>) dropped 26.10% to 19.92 on Phase 1 data.

Affymax (NASDAQ: <a class="ticker" href="/stock/affy#NASDAQ">AFFY</a>) dropped 19.23% to $1.68 after this morning's delisting.

Pandora (NASDAQ: <a class="ticker" href="/stock/p#NASDAQ">P</a>) fell 12.10% to $14.96 after reports of a possible Apple (NASDAQ: <a class="ticker" href="/stock/aapl#NASDAQ">AAPL</a>) iRadio reveal at WWDC.

AAPL

INFI

SNTA

Synta Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/snta#NASDAQ">SNTA</a>) shares dipped 32.93% to $4.95 after the company reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of ganetespib in second-line non-small cell lung cancer. 

Infinity Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/infi#NASDAQ">INFI</a>) shares lost 23.41% to $20.64 on Phase 1 data.

Affymax (NASDAQ: <a class="ticker" href="/stock/affy#NASDAQ">AFFY</a>) fell 22.60% to $1.61. Affymax's PEG ratio is -0.17.

National Bank of Greece SA (NYSE: <a class="ticker" href="/stock/nbg#NYSE">NBG</a>) dropped 12.60% to $6.31. The bank's trailing-twelve-month profit margin is -98.37%

Morning Market Losers

Affymax Says Received NASDAQ Delisting Letter on May 28th, NASDAQ Says Co. No Longer Has Operating Business

Nasdaq Sends Affymax Determination Letter Saying Company Should be Delisted -8K

Asset Sales

NKTR

Form 8-K Showing Affymax, Lonza Announces Sales Pact to End Supply Deal, Affymax Made $5.975M Payments to Lonza, Nektar

Source Close to Situation Says Affymax CFO Herbert Cross Still Working for Company, Declined Comment on Status of Operation

Many analysts declared Best Buy (NYSE: <a class="ticker" href="/stock/bby#NYSE">BBY</a>) close to dead, unable to compete with the likes of Amazon (NASDAQ: <a class="ticker" href="/stock/amzn#NASDAQ">AMZN</a>), Wal-Mart (NYSE: <a class="ticker" href="/stock/wmt#NYSE">WMT</a>), and even GameStop (NYSE: <a class="ticker" href="/stock/gme#NYSE">GME</a>). 

But, strong leadership in the way of decisive decisions form their CEO Hubert Joly has allowed the electronics retailer to themselves around. 

Brad Anderson, Best Buy board member and former CEO, went on CNBC's Squawk Box on Friday morning to talk about the company. 

"When you're under pressure, there's a proclivity to try to go back to the places where you can produce profit, and do it from the center. And it leads to things that are just insane," said Anderson. 

He said that when you loose focus on your costumer as a company, trouble will follow quickly. Anderson got involved with Best Buy again last year. That's when he and founder Richard Schulze attempted to acquire the company through private equity after seeing what he called "devastating" things transpire in regards to the company's long-term future. 

He said that during this time, Joly was appointed. Anderson called him an excellent leader, and said that he started to move the company in a direction. 

Anderson said that there's still much to do before Best Buy is in the position that it wants to be in, but that he feels encouraged about Joly's leadership in terms of where they're going to go.

But how does a company like Best Buy get an edge? 

"By focusing on the costumer, focusing specifically on what the costumer can't do, and inspiring people to go do what the costumer is looking for," said Anderson. 

Many costumers prefer trying out products like televisions, audio equipment and other more expensive items in-person, because they're performance-based. This might be an area of costumer service where they focus their attention the most in the years to come. 

Anderson said that Apple (NASDAQ: <a class="ticker" href="/stock/aapl#NASDAQ">AAPL</a>) is their real biggest competitor, noting that as a manufacturer they opened retail stores based on their specific idea of what a costumer experience should be. It's worked for Apple and their costumer base. 

In regards to the United States economy, Anderson said that big businesses are still pretty comfortable, and that it's small businesses that he worries about.

CNBC

Retail Sales

Media

AMZN

GOOG

ZUMZ

 Brad Anderson Hopes For Better Days in Best Buy's Future 

Press Releases

2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

Comments

Affymax

Affymax (AFFY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga